Pharming Group (NASDAQ:PHAR - Get Free Report) shares traded up 6.1% on Tuesday . The company traded as high as $10.29 and last traded at $10.29. 2,621 shares were traded during mid-day trading, a decline of 50% from the average session volume of 5,281 shares. The stock had previously closed at $9.70.
Analyst Ratings Changes
PHAR has been the subject of a number of research reports. HC Wainwright reissued a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, December 17th. Oppenheimer reduced their price objective on Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, October 28th. Finally, Jefferies Financial Group started coverage on Pharming Group in a research note on Monday, December 9th. They issued a "buy" rating and a $14.00 target price on the stock.
View Our Latest Research Report on Pharming Group
Pharming Group Price Performance
The firm has a market cap of $682.42 million, a P/E ratio of -38.69 and a beta of 0.05. The business's fifty day simple moving average is $8.49 and its 200-day simple moving average is $8.21. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.
Institutional Trading of Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,110 shares of the company's stock after purchasing an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
